This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Congress

Excellent survival rates reported for long-term entecavir or tenofovir therapy for chronic hepatitis patients

The 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting was held November 11-15 in Boston. A team of researchers led by George Papatheodoridis presented results from a 10-centre, large ongoing cohort study, which aimed to evaluate the survival in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis who had been treated with long-term entecavir (ENT) or tenofovir (TDF) therapy.

In the study population, 1-, 3-, 5- and 8-year overall survival rates were 99.7%, 97.7%, 95.8% and 94.0%, but were significantly higher in patients without cirrhosis (98.9%, 95.5%, 92.4% and 88.9%. When only liver related deaths or liver transplantation were taken into account, survival rates were 99.8%, 99.1%, 98.0% and 97.1%, and were also significantly higher in non-cirrhotics. However, the 1-, 3-, and 5-year survival rates of patients with hepatocellular carcinoma were considerably lower: 87.6%, 59.6%, 46.8%.

In conclusion, the survival of Caucasian CHB patients treated with ETV/TDF is excellent with >95% of cases surviving at 5 years. However, HCC Is a major factor affecting the overall mortality and the only factors affecting liver related mortality in such patients.

References

  1. Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Hepatocellular carcinoma (HCC) is the only factor affecting the excellent survival of Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy. The Liver Meeting 2016: Abstract 68. Hepatol 2016; 64 (1; supplement): 35-36A